Joon Sang Lee

Joon Sang Lee

Auto-generated profile, based on publicly available information

Joon Sang Lee

16Sanofi, Cambridge, Massachusetts

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2023 in Nature Reviews Drug Discovery
Verified
Journal Article
Open access
PDF file
BSBram Van de Sande
Bram Van de Sande
JLJoon Sang Lee
Joon Sang Lee
EMEuphemia Mutasa-Gottgens
Euphemia Mutasa-Gottgens
BNBart Naughton
Bart Naughton
WBWendi Bacon
Wendi Bacon
EFEdgardo Ferran
Edgardo Ferran
Single-cell technologies, particularly single-cell RNA sequencing (scRNA-seq) methods, together with associated computational tools and the growing availability of public data resources, are transforming drug discovery and development. New opportunities are emerging in target identification owing to improved disease understanding through cell subtyping, and highly multiplexed functional genomics screens incorporating scRNA-seq are enhancing target credentialling and prioritization. ScRNA-seq is also aiding the selection of relevant preclinical disease models and providing new insights into drug mechanisms of action. In clinical development, scRNA-seq can inform decision-making via improved biomarker identification for patient stratification and more precise monitoring of drug response and disease progression. Here, we illustrate how scRNA-seq methods are being applied in key steps in drug discovery and development, and discuss ongoing challenges for their implementation in the pharmaceutical industry.

15 July 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
ABAditya Bardia
Aditya Bardia
SCSarat Chandarlapaty
Sarat Chandarlapaty
HLHannah M. Linden
Hannah M. Linden
GUGary A. Ulaner
Gary A. Ulaner
AGAlice Gosselin
Alice Gosselin
MCMario Campone
Mario Campone
AMEERA-1 is a Phase 1/2 open-label single-arm study evaluating once-daily (QD) amcenestrant, an orally bioavailable selective estrogen receptor (ER) degrader, in postmenopausal women with ER+/HER2− advanced breast cancer (NCT03284957), who were mostly heavily pretreated (including targeted therapies and fulvestrant). In the dose escalation phase (Part A: n = 16), patients received amcenestrant 20-600 mg QD. Based on absence of dose-limiting toxicities, paired functional 18F-fluoroestradiol positron emission tomography, and pharmacokinetics, 400 mg QD was selected as recommended Phase 2 dose (RP2D) for the dose expansion phase (Part B: n = 49). No Grade ≥3 treatment-related adverse events or clinically significant cardiac/eye toxicities were reported. The Part B primary endpoint, confirmed objective response rate (ORR) was 3/45 at the interim analysis and 5/46 (10.9%) at the final analysis. The overall clinical benefit rate (CBR) was 13/46 (28.3%). CBRs among patients with baseline wild-type and mutated ESR1 were 9/26 (34.6%) and 4/19 (21.1%), respectively. Paired tumor biopsy and cell-free DNA analyses revealed ER inhibition and degradation, and a reduction in detectable ESR1 mutations, including Y537S. In conclusion, amcenestrant at RP2D of 400 mg QD for monotherapy is well-tolerated with no dose-limiting toxicities, and demonstrates preliminary antitumor activity irrespective of baseline ESR1 mutation status.

28 March 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
OBOliver Bechter
Oliver Bechter
CLCarmen Loquai
Carmen Loquai
SCStephane Champiat
Stephane Champiat
JBJean-Francois Baurain
Jean-Francois Baurain
JGJean-Jacques Grob
Jean-Jacques Grob
Céleste LebbéCéleste Lebbé
Céleste Lebbé
Purpose: We investigated SAR441000 (mixture of four mRNAs encoding IL-12, single-chain IFN-α-2b, GM-CSF, and IL-15 sushi domain) alone or in combination with cemiplimab in patients with advanced solid tumors. Patients and Methods: SAR441000 was intratumorally administered weekly in a 4-week cycle in monotherapy and in a 3-week cycle at a predefined dose level with 350 mg cemiplimab (intravenously) every 3 weeks in combination therapy. The primary objective was to determine MTD or maximum administered dose, overall safety, tolerability, and objective response rate of SAR441000. Results: We enrolled 77 patients previously treated with anticancer therapies [escalation monotherapy: N = 21; escalation combination: N = 15; and expansion combination (PD-1–refractory melanoma): N = 41]. The maximum administered dose at dose level 8 was 4,000 µg. The most common grade ≥3 treatment–related adverse events was fatigue in the escalation phase (monotherapy: 28.6% and combination therapy: 66.7%) and injection-site pain (31.7%) in the expansion phase. In combination therapy, one patient in the escalation phase and two patients in the expansion phase achieved partial responses. At 4,000 μg (highest dose) across all cohorts, the maximum fold change in plasma cytokine concentration was the highest and lowest for IFN-α-2 (74.9-fold) and IL-15 (1.96-fold), respectively. Increased blood IFN-γ and inducible protein-10 levels were observed for most patients. Conclusions: Intratumoral administration of SAR441000 in combination with cemiplimab was generally well tolerated with antitumor activity in the locoregional disease setting. Anecdotal evidence of pharmacodynamic immunomodulatory effect and distant noninjected lesion antitumor response was observed, without significant effects in patients with advanced solid tumors previously treated with anti–PD-1 therapies.


13 June 2025
Verified
Other
Open access
OBOliver Bechter
Oliver Bechter
CLCarmen Loquai
Carmen Loquai
SCStephane Champiat
Stephane Champiat
JBJean-Francois Baurain
Jean-Francois Baurain
JGJean-Jacques Grob
Jean-Jacques Grob
Céleste LebbéCéleste Lebbé
Céleste Lebbé
Best percentage change in lesion diameters from baseline (RECIST 1.1). A) Escalation monotherapy a,b; B) Expansion combination cohortb,c (melanoma patients)